There was a 2015 Phase I human trial registered to study safety and pharmacokinetics, but published results are conspicuously missing
Walk in, get your shot, and get on with your day
The peptide does not appear to significantly affect glucose metabolism or insulin sensitivity in the way that full-length growth hormone does - growth hormone causes insulin resistance through various mechanisms, whereas AOD9604 has been reported to be neutral or possibly even beneficial for insulin sensitivity
In these individuals, methylfolate or folinic acid may represent a more appropriate choice
This product works and this company ships fast
Typical Starting Protocol Sermorelin: 100-200 mcg subcutaneous CJC-1295 (no DAC / Mod GRF 1-29): 100-200 mcg subcutaneous Both injected simultaneously, same syringe or adjacent sites, at bedtime Frequency: 5 nights per week (Monday through Friday), cycling off weekends to reduce pituitary desensitization risk Total GHRH-equivalent stimulus per injection in the stack is therefore 200-400 mcg, which is within the dose range studied in sermorelin monotherapy trials [1] and in the Jett pharmacokinetic study for CJC-1295 [2]
